Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of RGH-188 in the Acute Exacerbation of Schizophrenia

NCT00404573 is registered in ClinicalTrials.gov with Forest Laboratories as lead sponsor.

NCT NCT00404573
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00404573 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of RGH-188 in the Acute Exacerbation of Schizophrenia
Lead sponsor
Forest Laboratories
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2006
Completion date
Not reported
Enrollment
375 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia